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p52 expression enhances lung 
cancer progression
Jamie A. Saxon1, Hui Yu2,3, Vasiliy V. Polosukhin4, Georgios T. Stathopoulos  5,6, Linda A. 
Gleaves4, Allyson G. McLoed1, Pierre P. Massion  1,4,7, Fiona E. Yull1, Zhongming Zhao1,2,3 & 
Timothy S. Blackwell1,4,7,8
While many studies have demonstrated that canonical NF-κB signaling is a central pathway in 
lung tumorigenesis, the role of non-canonical NF-κB signaling in lung cancer remains undefined. 
We observed frequent nuclear accumulation of the non-canonical NF-κB component p100/p52 in 
human lung adenocarcinoma. To investigate the impact of non-canonical NF-κB signaling on lung 
carcinogenesis, we employed transgenic mice with doxycycline-inducible expression of p52 in airway 
epithelial cells. p52 over-expression led to increased tumor number and progression after injection 
of the carcinogen urethane. Gene expression analysis of lungs from transgenic mice combined with 
in vitro studies suggested that p52 promotes proliferation of lung epithelial cells through regulation 
of cell cycle-associated genes. Using gene expression and patient information from The Cancer 
Genome Atlas (TCGA) database, we found that expression of p52-associated genes was increased in 
lung adenocarcinomas and correlated with reduced survival, even in early stage disease. Analysis of 
p52-associated gene expression in additional human lung adenocarcinoma datasets corroborated 
these findings. Together, these studies implicate the non-canonical NF-κB component p52 in lung 
carcinogenesis and suggest modulation of p52 activity and/or downstream mediators as new 
therapeutic targets.
Lung cancer is the leading cause of cancer-related death in the U.S, with an estimated 224,390 new lung cancer 
diagnoses in 2016 and a 5-year survival rate of less than 20 percent1. In addition to emphasizing the need for 
better understanding of tumor biology and development of new therapeutic approaches, available epidemiolog-
ical data suggest that identification of biomarkers for improved outcome prediction beyond the current staging 
system would be valuable for guiding appropriate use of available treatment strategies.
Numerous studies have demonstrated the critical role of epithelial NF-κB signaling in lung cancer2–4. The 
NF-κB transcription factor family contains 5 members (p65/RelA, p52, p50, RelB, and c-Rel) and can be activated 
through either canonical or non-canonical signaling pathways. Canonical pathway activation occurs when inhib-
itory IκBs are phosphorylated, releasing p65/p50 heterodimers to translocate into the nucleus. Non-canonical 
NF-κB signaling is defined by nuclear accumulation of p52, which hinges on proteolytic processing of p100 
removing an inhibitory C-terminal domain and resulting in p52 activation. p52 is then able to enter the nucleus, 
typically as a heterodimer bound to RelB. Although components of both the canonical and non-canonical NF-κB 
signaling pathways are activated in a number of malignancies, including lung cancer5–7, studies of NF-κB in cancer 
have mainly focused on canonical pathway signaling, leaving the non-canonical pathway largely uninvestigated.
The majority of knowledge regarding in vivo functions of p100/p52 relate to its role in lymphoid develop-
ment and hematopoietic disease. Mice with global knockout of the Nfkb2 gene, which encodes p100, demon-
strate defective dendritic cell function, B-cell maturation, T-cell responses, and secondary lymphoid organ 
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development8,9, presumably due to the role of p52 in regulating expression of chemokine genes important for 
normal lymphoid organogenesis10. In several hematopoietic malignancies, including multiple myeloma, chronic 
lymphocytic leukemia, and B- and T-cell cutaneous lymphomas, chromosomal translocations in the Nfkb2 gene 
have been identified that truncate the C-terminus, thus removing the inhibitory domain11–13. These truncated 
proteins localize in the nucleus, leading to constitutively active p5211. Knock-in mice that express truncated Nfkb2 
develop enlarged lymph nodes and hyperactive T cell responses, providing some insight into the function of acti-
vated p52 in hematopoietic diseases14. However, these mice die prematurely due to significant gastric hyperplasia, 
hinting that dysregulated p52 activation could also play a role in epithelial-based disorders.
Increased activation of p52 has been observed in lung6, breast15, prostate16,17, and pancreatic cancers18; how-
ever, studies on the effects of p52 activation in cancers of epithelial origin have been limited due to lack of appro-
priate in vivo models. Here, we use a transgenic mouse model with inducible expression of p52 in the airway 
epithelium (designated CCSP-p52) to investigate a potential role for p52 in lung tumorigenesis. Together, these 
studies define a role for p52 in lung tumorigenesis and identify a p52-associated gene network that is highly cor-
related with patient prognosis.
Results
p100/p52 expression is common in human lung adenocarcinoma. To examine the distribution of 
p100/p52 expression in human lung adenocarcinoma, we performed p100/p52 immunostaining on a lung ade-
nocarcinoma tissue microarray (TMA) (Fig. 1A, Table 1). We observed p100/p52 expression in all lung adenocar-
cinomas tested (34/34) (Fig. 1B). Multiple samples from each tumor were present on the array, and each sample 
was scored on a 0 to 4 point scale based on the intensity and the localization of p100/p52 staining. We calculated 
an average p100/p52 expression score for each tumor and found that 47% (16/34) of tumors had mean scores > 2, 
indicating substantial nuclear staining for p52. In contrast, minimal p100/p52 expression was observed in normal 
lung parenchyma (Fig. 1A). Together, these observations suggest that p100/p52 expression and p52 activation are 
common in lung adenocarcinomas.
CCSP-p52 mice develop an increased tumor burden and more advanced lesions. In order to 
investigate the effect of p52 expression during lung tumorigenesis, we employed CCSP-p52 mice, which inducibly 
express FLAG-tagged murine p52 in Clara cell secretory protein (CCSP)-positive epithelial cells19. These mice 
exhibit normal lung histology after p52 over-expression19. To induce tumors in CCSP-p52 mice, we used the lung 
carcinogen urethane (ethyl carbamate), which causes tumors primarily through Kras mutations20 and, in FVB 
Figure 1. p100/p52 expression is present in human lung adenocarcinomas. (A) Representative images of p100/
p52 immunostaining of lung adenocarcinoma and normal lung tissue (40x magnification; scale bar = 100 µm). 
(B) Distribution of p100/p52 immunostaining on a tumor tissue microarray (TMA) from 106 human lung 
adenocarcinoma samples obtained from 34 patients. Tumor spots were scored as follows: 0 = no staining; 1 = diffuse 
cytoplasmic staining, no nuclear staining; 2 = dark granular cytoplasmic staining, no nuclear; 3 = nuclear staining in 
<25% of tumor cells; 4 = nuclear staining in >25% of tumor cells. Each tumor had at least two spots on the TMA, and 
the mean score was calculated for each tumor based on the individual score for each spot.
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background mice, induces a mild inflammatory response2. We first examined the effects of p52 over-expression on 
urethane-induced inflammation and atypical adenomatous hyperplasia (AAH) formation. For these experiments, 
CCSP-p52 and wild-type (WT) mice were treated with dox for one week followed by a single intraperitoneal (IP) 
injection of urethane (1 g/kg) and remained on dox until euthanized. Total inflammatory cells in bronchoalveolar 
lavage (BAL) were counted at 10 days, 21 days (3 weeks), and 42 days (6 weeks) after urethane injection. No differ-
ences were observed between CCSP-p52 and WT mice at any time point (Supplementary Fig. S1A). In addition, 
no differences in AAH lesion numbers were detected at 6 weeks post-urethane (Supplementary Fig. S1B).
To investigate later stages of tumor formation, CCSP-p52 and WT mice were treated with dox for one week 
followed by 4 weekly IP urethane injections. Mice remained on dox treatment until sacrifice 6 months after the 
first urethane injection. Lung tumor dimensions were measured, and lung tumors enumerated on lung sections, 
revealing a significant increase in tumor number and tumor size in CCSP-p52 lungs compared to WT (Fig. 2A 
and B). We further analyzed these tumors by histology, classifying tumors as adenomas, minimally invasive ade-
nocarcinomas (MIAs), or adenocarcinomas. Compared to WT mice, CCSP-p52 mice had an increased propor-
tion of advanced lesions (MIAs and adenocarcinomas, Χ2 p < 0.0001) (Fig. 2C and D). In comparison, long-term 
p52 expression alone resulted in sustained p52 expression but no evidence of inflammation or tumor formation 
(Supplementary Fig. S2). Taken together, these studies demonstrate that p52 expression augments lung tumor 
formation and contributes to enhanced tumor progression.
p52 expression enhances proliferation through regulation of cell cycle genes. To understand 
the mechanism by which p52 expression augments tumorigenesis, we performed microarray gene expression 
analysis using mRNA isolated from lungs of CCSP-p52 and WT mice on dox for 1 week. Genes were ranked 
based on the log fold change (logFC) of expression between WT and CCSP-p52 mice using a cut-off of 0.41 
(approximately 30% increase in gene expression in CCSP-p52 mouse lungs) (Fig. 3A). To evaluate the poten-
tial relevance of p52-regulated genes in human lung tumors, we focused only on genes that had known human 
homologs and were present in The Cancer Genome Atlas (TCGA) expression data from lung adenocarcinoma 
patients. Using these criteria, a total of 71 genes associated with increased p52 expression were identified (Fig. 3A 
and B; Supplementary Table S1). Quantitative PCR was performed to validate increased expression of selected 
genes from the 71 gene list in CCSP-p52 lungs (Fig. 3C–E). To elucidate gene functions, we identified biological 
processes that were enriched in the p52-associated gene set using a Gene Ontology (GO) analysis. Applying a 
false discovery rate (FDR) of 0.001, we found that p52-associated genes were over-represented in processes related 
to cell cycle progression (Table 2), suggesting that p52 regulates expression of genes involved in proliferation. To 
validate this finding, we used a stable p52-expressing rat lung epithelial cell line (RLE-p52) generated previously19. 
We found that BrdU incorporation was enhanced in RLE-p52 cells compared to empty vector (RLE-EV) (Fig. 3F), 
indicating that p52 stimulates proliferation of lung epithelial cells.
Expression of p52-associated genes predicts prognosis of lung cancer patients. To investigate 
the relevance of p52 expression in human lung cancer, we examined expression of the 71 identified p52-associated 
genes in matched lung cancer and normal samples. A differential expression test using the paired t-test was per-
formed for each gene in paired tumor and normal samples from 54 lung adenocarcinoma patients available in the 
TCGA dataset. Up-regulated genes were defined as having both a logFC > 1 and false discovery rate (FDR) < 0.01. 
From the set of 20,501 genes, 1,274 up-regulated genes (6.2%) were identified in tumors compared to matched 
normal samples (Fig. 4A). Of the 71 p52-associated genes, 35 were up-regulated in tumors (49.3%), indicating a 
significant over-representation of p52-associated genes in tumor samples compared to normal (hypergeometric 
Factor n Mean ± SE
Age (years)
   ≤60 12 54.41 ± 1.31
   >60 21 67.95 ± 0.99
   Unknown 1
Ever Smoker
   Yes 32
   No 1
   Unknown 1
Pack Years
   ≤50 16 34.99 ± 2.33
   >50 15 109.95 ± 11.90
   Unknown 1
Stage at Diagnosis
Stage I (A and B) 22
Stage II (A and B) 5
Stage III (A and B) 5
Unknown 2
Table 1. Clinicopathological characteristics of patient samples.
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test p = 6.0 × 10−25) (Fig. 4A,B and Supplementary Table S1) and suggesting that p52 could be important in 
human lung tumors.
Since we observed more advanced tumors in urethane-treated CCSP-p52 mice, we wondered whether 
increased p52 expression would correlate with a worse prognosis in lung cancer patients. Therefore, we investi-
gated the relationship between increased expression of p52-associated genes and patient outcomes using tumor 
expression data and clinical information from the TCGA dataset. 437 primary lung adenocarcinoma samples 
were divided into two equal groups based on the collective expression level of the 71 p52-associated genes by 
summing expression from all 71 genes (Supplementary Table S2). Kaplan-Meier survival analysis revealed that 
patients with high expression of p52-associated genes had a significantly worse prognosis (log-rank test p = 0.004) 
(Fig. 4C). To validate this analysis, we divided patients by a second method into two groups based on summed 
“votes” from the 71 genes. In this analysis, one gene counted as a vote for one sample if its expression in the 
sample was equal to or higher than the median expression level for this gene across samples, thus preventing a 
tumor sample with only a few highly-expressed genes from being placed in the “high expression group”. Using 
this method, Kaplan-Meier survival analysis again revealed that patients with high expression of p52-associated 
Figure 2. p52 over-expression results in increased tumor number, size, and progression. (A) Average tumor 
number per lung section and (B) average tumor area from WT and CCSP-p52 mice 6 months after urethane 
injection (3 sections/mouse; n = 13–14 mice/group; *p < 0.05 compared to WT mice.). (C) Number and 
(D) proportion of lung tumors classified as adenomas, minimally invasive adenocarcinomas (MIA), or 
adenocarcinomas (n = 13–14 mice/group; *Χ2 p < 0.0001 for comparing total number of advanced lesions 
[MIAs and adenocarcinomas] between CCSP-p52 and WT mice).
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genes had significantly worse outcomes (log-rank test p = 0.021) (Supplementary Fig. S3A). Furthermore, sur-
vival analysis of only Stage I patients revealed that patients with high expression of p52-associated genes still had 
a significantly worse prognosis (log-rank test p = 0.036) (Fig. 4D). Together, these data suggest that expression of 
p52-associated genes in tumors of lung cancer patients leads to shorter survival and can be used to predict patient 
outcome in early stage lung cancer patients.
Since the GO analysis suggested that p52 regulates a number of genes that have highly related functions, we 
extracted a protein subnetwork connecting the p52-associated genes from a human protein-protein interaction 
Figure 3. Identification of p52-regulated genes by microarray analysis. (A) Schematic of process used to 
identify p52-regulated genes from microarray data generated from pooled mRNA samples from lungs of WT 
and CCSP-p52 mice on dox for 1 week (n = 4/group). (B) Volcano plot of log fold changes and differential 
expression p-values comparing CCSP-p52 mice to WT. Black dots represent all genes in the expression data 
matrix. Red dots represent 71 genes identified for further analysis. (C–E) Expression microarray data validation 
by quantitative PCR of identified p52-regulated genes Ccna2 (C), Top2a (D), and Ube2c (E) measured in whole 
lung RNA from WT and CCSP-p52 mice on dox for 1 week (n = 6 mice/group; *p < 0.05 compared to WT). 
(F) Quantification of BrdU incorporation of RLE-p52 and RLE-WT cells, normalized to total viable cells 
(**p < 0.01 compared to RLE-EV).
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network. The 35 p52-associated genes identified in tumor versus normal samples were used to generate a network 
consisting of genes from the p52-associated gene list as well as 13 imputed mediator genes (Fig. 4E). To test the 
strength of this protein interaction network, a survival analysis was performed based only on expression of the 
13 imputed mediator genes. High expression of the imputed genes also correlated with shorter survival (log-rank 
test p = 0.047 by expression summation, p = 0.097 by votes) (Fig. 4F and Supplementary Fig. S3B), supporting the 
strength of this p52-derived interaction network in predicting patient prognosis.
We further validated our original 71 p52-associated gene signature in additional human lung adenocarci-
noma datasets. Using normal and lung adenocarcinoma expression data from the BATTLE study21,22, we per-
formed unsupervised hierarchical clustering and found that this p52-associated gene signature segregated normal 
and lung adenocarcinoma samples (Fisher’s exact test p = 0.000003) (Fig. 5A). We then performed a differential 
expression test for each gene in normal and lung adenocarcinoma samples, defining up-regulated genes as having 
both a logFC > 1.3 and FDR < 0.01. From the entire set of 22,216 genes, 9,832 (44.3%) were significantly upreg-
ulated in tumors compared to matched normal samples whereas 54 (76.1%) of the 71 p52-associated genes were 
up-regulated in tumors, demonstrating a significant over-representation of p52-associated genes in tumor sam-
ples compared to normal in a second independent dataset (Fisher’s exact test p = 0.0034) (Fig. 5B). When evalu-
ated as a group, mRNA levels of the 71 p52-associated genes were significantly increased in lung adenocarcinoma 
samples compared to normal lung tissue (p < 0.0001) (Fig. 5C). In addition, we assessed the relationship between 
p52 expression and survival of lung adenocarcinoma patients in a composite dataset that includes expression data 
from several lung cancer cohorts23. Higher p100/p52 (Nfkb2) expression in lung adenocarcinomas correlated 
with reduced patient survival (p = 3 × 10−7) (Supplementary Fig. S4B). In contrast, higher expression of Nfkb1, 
which encodes for the NF-κB family member p50, correlated with improved survival (p = 0.017) (Supplementary 
Fig. S4A).
Discussion
These studies provide evidence of the functional involvement of non-canonical NF-κB signaling in lung car-
cinogenesis, identifying p52 as a novel mediator of lung cancer progression. In human lung adenocarcinoma 
tumors, we observed frequent nuclear accumulation of p52, suggesting that p52 activation is common in lung 
carcinogenesis. Using transgenic mice with inducible expression of p52 in the airway epithelium, we found that 
p52 over-expression led to more tumors, larger tumors, and more advanced tumors after urethane injection. Our 
in vitro studies and gene expression microarray analysis suggest that p52 enhances tumor burden through the 
regulation of cell cycle genes that promote proliferation. Expression of p52-associated genes was significantly 
associated with lung tumors and increased expression of genes from a p52-derived protein-protein interaction 
network correlated with significantly reduced survival, even for Stage I patients. These findings have important 
implications for investigations into modulation of p52 or its downstream targets as a novel therapeutic approach 
in lung cancer.
Even though nuclear localization of p52 has been observed in a number of different tumor types, our under-
standing of the function of p52 activation in vivo during carcinogenesis has remained limited due to the con-
straints of available models. In other studies using a mouse model with global truncation of the Nfkb2 gene 
deleting the C-terminal inhibitory domain of p100, mice die from gastric hyperplasia14. However, unlike our stud-
ies, the individual contribution of inflammatory cells and surrounding stroma with dysregulated p52 activation 
was not separated from the effects of p52 activation in the epithelial cells of the stomach. Using a transgenic model 
with expression of the full Nfkb2 gene under the control of the β-lactoglobulin milk protein promoter, Connelly 
et al. demonstrated ductal thickening and hyperplasia in the mammary gland after repeated pregnancies24, but 
in this model, expression was limited to the periods of milk production during the late stages of pregnancy and 
lactation. Our studies improved upon these models by using an inducible p52-expressing mouse. The advantages 
of a mouse model with inducible p52 expression are that p52 can be expressed with any cell type-specific pro-
moter coupled to a reverse tetracycline transactivator, the duration of p52 expression can be manipulated, and 
p52 expression can be combined with other inducible mouse models, including oncogenic tumor models. Future 
studies using this p52-inducible model to modulate the duration of expression in the urethane model and to 
express p52 in other cell types and in combination with other inducible models will be valuable for developing a 
broader understanding of p52 activation in lung cancer and other contexts.
Gene Ontology term (Biological Process) Reference set size Expected Count Observed count Adjusted p-value1
Cell cycle checkpoint 230 0.98 9 2.59E-05
Mitotic cell cycle phase transition 443 1.88 11 8.83E-05
DNA unwinding involved in DNA replication 8 0.03 3 1.39E-04
Regulation of cell division 221 0.94 8 1.39E-04
Regulation of attachment of spindle 
microtubules to kinetochore 9 0.04 3 1.81E-04
DNA replication initiation 29 0.12 4 1.88E-04
Regulation of cell cycle process 435 1.85 10 3.68E-04
Chromosome organization 765 3.25 13 4.04E-04
Spindle assembly involved in mitosis 15 0.06 3 7.44E-04
Table 2. Gene ontology (GO) analysis of p52 regulated genes (FDR = 0.001). 1p-values have been adjusted 
using the Benjamini-Hochberg method.
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Although p100/p52 expression appears to be common in lung adenocarcinomas, how this pathway becomes 
activated remains unclear. Proteolytic processing of p100 to p52 can be activated by a number of stimuli, includ-
ing lymphotoxin β10, CD40 ligand25, reactive oxygen species26, and STAT3 signaling27, suggesting that p52 activa-
tion can occur in a tumor as a result of oncogenic signaling or microenvironmental stimuli. Additional evidence 
indicates that crosstalk occurs between the canonical and non-canonical NF-κB pathways, suggesting that factors 
leading to canonical pathway activation could also activate p5228.
Like CCSP-p52 mice, activation of canonical NF-κB signaling in transgenic mice expressing constitu-
tively active IKKβ in airway epithelium increases tumor burden following urethane treatment29. In this model, 
Figure 4. Expression of p52-associated genes correlates with prognosis of lung cancer patients. (A) Global 
and p52-associated genes upregulated in matched tumor and normal samples (n = 54) from TCGA dataset. 
Up-regulated genes were defined as logFC > 1 and FDR < 0.01 (hypergeometric test p = 6.0 × 10−25). (B) 
Volcano plot of log fold changes and differential expression p-values of tumor versus normal samples. Black 
dots represent all genes in the expression data matrix. Red dots represent p52-associated genes. (C,D) Kaplan-
Meier survival curves of overall (C) and Stage I (D) patient survival data based on summed expression 
of p52-associated genes in tumors (log-rank test, p = 0.004 for overall; p = 0.036 for Stage I). (E) Protein-
protein interaction network generated using 35 p52-associated genes associated with tumors (see Fig. 4A and 
Supplementary Table S1). Pink circles are genes identified as p52-regulated genes through microarray analysis, 
and blue circles are imputed genes. (F) Kaplan-Meier survival curve of overall patient survival based on 
summed expression of imputed mediator genes (log-rank test, p = 0.047).
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canonical NF-κB activation causes a robust immune/inflammatory response, which promotes lung carcinogen-
esis through paracrine signaling29,30. In contrast, our studies indicate that non-canonical NF-κB signaling likely 
regulates genes that function in a cell autonomous manner to promote carcinogenesis.
Our finding that p52 can promote proliferation of airway epithelial cells during lung carcinogenesis is some-
what unexpected, as several previous studies investigating p52 expression in airway epithelial cells have shown 
that p52 can promote apoptosis of Club cells in vivo19 and contribute to regulation of inflammatory cytokines in 
vitro31. In other studies using in vitro and xenograft models, however, p52 activation has been shown to promote 
Figure 5. Increased expression of p52-associated genes in lung adenocarcinoma samples from the BATTLE 
study. (A) Hierarchical clustering based on expression of 71 p52-associated genes in normal lung (n = 30) and 
lung adenocarcinoma (LADC) (n = 80) tissues. (Fisher’s exact test p = 0.000003). (B) p52 signature and global 
genes over-represented in lung adenocarcinoma samples compared with normal lung. Up-regulated genes were 
defined as logFC > 1.3 and FDR < 0.01 (Fischer’s exact test P = 0.0034). (C) mRNA transcript expression levels 
from 71 p52-associated genes in normal lung tissue and lung adenocarcinoma samples. Raw data points and 
median with error bars that represent interquartile range are shown. Transcripts were not normally distributed 
by the Kolmogorov-Smirnov normality test and were hence analyzed by the Wilcoxon matched-pairs signed 
rank test (****p < 0.0001).
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cell proliferation. Nadiminty et al. observed that p52 over-expression enhanced proliferation of prostate cancer 
cells in androgen-deprived conditions by stimulating Cyclin D1 expression32. Similarly, increased p100 expression 
in mammary glands led to hyperplasia and increased Cyclin D124. Although we did not identify Cyclin D1 as an 
upregulated gene in our microarray analysis, both Cyclin E2 and Cyclin A2 were increased in CCSP-p52 lungs 
(Supplementary Table S1).
Among NF-κB family members, p52 is structurally most similar to p50. Kravtsova-Ivantsiv and colleagues 
found that p50 over-expression inhibits tumor growth in xenograft models33, and our survival analysis based on 
p50 expression in lung adenocarcinomas supports their observations. Despite the structural similarity between 
p50 and p52, we found that p52 over-expression enhances tumorigenesis and leads to reduced survival. These 
studies suggest that p52 and p50 function differently during tumorigenesis, which may be due to the differen-
tial affinities of each for specific promoter sequences or their propensity to interact with other NF-κB family 
members and transcriptional binding partners34,35. While nuclear p52 accumulation is considered indicative of 
non-canonical NF-κB pathway activation, a study by Zhao, et al. suggests that p52 is capable of forming heterod-
imers with all of the other NF-κB family members34. In addition, p52 has been shown to interact with Bcl-336–39, 
p5340, and multiple epigenetic modifiers, including CBP, p300, and HDAC proteins38,40–43, and these interactions 
can be activating or inhibitory depending on the context. Future studies are necessary to understand p52 interac-
tions in the nucleus and the mechanisms by which p52 influences tumor formation and progression.
In these studies, we took a gene list derived from p52 over-expression in a mouse model and demonstrated 
that these genes predict survival of early stage lung cancer patients. In addition, p52 expression in lung adenocar-
cinomas was inversely correlated with survival, similar to previous reports with the NF-κB family members p65 
and RelB44,45. Although differences in gene expression between CCSP-p52 and WT mouse lungs were relatively 
modest, likely due to the small subset of transgene-expressing lung epithelial cells, we were able to identify genes 
with significant expression changes as a result of p52 over-expression, and these genes were highly related in 
function, indicating that p52 regulates expression of a network of related genes. Using gene expression profiling 
of Nfkb2 knockdown fibroblasts, Ianetti et al. described corresponding changes in several of the same genes iden-
tified in our study, supporting our identification of a discrete set of p52 target genes26. However, future studies 
comparing p52-induced gene expression changes during different stages of carcinogenesis and in the context of 
different oncogenic stimuli could be helpful for revealing additional p52 target genes.
Since our data suggest that p52 regulates a network of known cell cycle regulators that have well-established 
roles in carcinogenesis, p52 modulation may be an attractive therapeutic target for drug development. Although 
there are no available methods to directly target p52 at present, inhibitors for several of the nodes in our 
p52-derived protein interaction network have been developed and are being tested in clinical trials, including 
aurora kinase B, cyclin dependent kinase 1, and polo-like kinase 1, suggesting that treatment with these drugs 
alone or in combination may be beneficial in patients with p52 activation in their tumors.
Materials and Methods
Animal model. CCSP-tTS/(tet-O)7-FLAG-p52 mice on an FVB background were bred to CCSP-rtTA 
homozygous mice (gift from Dr. J.A. Whitsett, University of Cincinnati, Cincinnati, OH) to generate CCSP-p52 
mice, which inducibly express FLAG-tagged p52 in the airway epithelium as previously described19. CCSP-p52 
mice generated from two separate CCSP-tTS/(tet-O)7-FLAG-p52 founder lines were used for these studies. Age- 
and sex-matched transgenic mice along with genotype-negative littermate controls (called WT in our studies) 
were used in experiments. Transgene expression was activated by administering doxycycline (dox, Sigma) at 
a concentration of 2 g/L along with 2% sucrose in drinking water. For urethane experiments, mice were placed 
on dox for 1 week prior to IP injection of urethane (1 g/kg body weight; Sigma-Aldrich) and remained on dox 
until euthanized. For 6 month tumorigenesis experiments, mice received weekly IP injections of urethane for 4 
weeks. At sacrifice, lungs were lavaged, and total and differential BAL cell counts were determined as previously 
described2,29. The left lung was tied off and frozen, and the right lung was perfused and fixed by inflating with 10% 
neutral-buffered formalin. All animal studies were approved and conducted according to the guidelines of the 
Vanderbilt University Medical Center Institutional Animal Care and Use Committee.
Histology and immunostaining. After fixation, lungs were embedded in paraffin, sectioned (5 µm), 
and hematoxylin and eosin (H&E)-stained for histological analysis and quantification of tumor burden. Three 
sections were analyzed per mouse, and each section was separated by 50 µm. Tumor area was measured using 
Image-Pro Plus software (Media Cybernetics), and tumor number was enumerated on each section. AAH lesions 
and tumor histology were assessed by a pathologist blinded to the experimental groups. Tumors were classified as 
adenomas (clear border), minimally invasive adenocarcinomas (MIAs; border mostly defined with one invasive 
edge), and adenocarcinomas (locally invasive with no defined border). To assess p100/p52 expression in human 
lung adenocarcinomas, immunostaining using a p100/p52 antibody (C-5, Santa Cruz) was performed on a lung 
tumor tissue microarray (TMA) with 106 adenocarcinoma samples (spots) from 34 patients. Collection of tumor 
samples for generating the TMA was carried out in accordance with relevant guidelines and regulations, and 
experimental protocols were approved by the Vanderbilt University Medical Center Institutional Review Board 
(IRB 000616). Informed consent was obtained from all subjects. p100/p52 staining of tumor spots was scored by 
two independent readers. Scoring was performed as follows: 0 = no staining; 1 = diffuse cytoplasmic staining, no 
nuclear staining; 2 = dark granular cytoplasmic staining, no nuclear; 3 = nuclear staining in <25% of tumor cells; 
4 = nuclear staining in >25% of tumor cells. Each tumor had at least two spots on the TMA, and the mean score 
was calculated for each tumor based on the individual score for each spot.
www.nature.com/scientificreports/
1 0SCientifiC RepoRts |  (2018) 8:6078  | DOI:10.1038/s41598-018-24488-8
Western blot analysis. Nuclear protein was prepared from lung tissue using the NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (Thermo Scientific), separated by SDS-PAGE gel, transferred to nitrocellulose 
membranes, and probed using p100/p52 (4882, Cell Signaling) and nuclear loading control TATA-binding pro-
tein (TBP) (N-12, Santa Cruz). Immunodetection was performed using the corresponding AlexaFluor-conjugated 
antibodies and the Odyssey Infrared Imaging System (LI-COR Biosciences). All images were converted to 
grayscale.
In vitro proliferation measurements. Rat type II alveolar epithelial cell line RLE-6TN was obtained from 
ATCC and maintained at 37 °C 5% CO2 in DMEM (Invitrogen) with 4.5 g/l glucose and 2 mM L-glutamine, sup-
plemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. Cells were tested 
periodically for mycoplasma contamination using the Universal Mycoplasma Detection Kit (ATCC). Generation 
and validation of stable p52 over-expressing (RLE-p52) and control empty vector (RLE-EV) cells are described 
elsewhere19. RLE-EV and RLE-p52 cells were plated in 96 well plates for viability and BrdU incorporation meas-
urements. 48 hours after plating, cells were incubated with BrdU for 4 hours, and BrdU incorporation was meas-
ured using the chemiluminescent BrdU Cell Proliferation ELISA (Roche). To ensure plating of equal numbers of 
cells, viability of RLE-EV and RLE-p52 cells was measured on the same day as a surrogate for cell number using 
the CellTiter-Glo Luminescent Cell Viability assay (Promega) according to the manufacturer’s protocol.
Microarray gene expression analysis. The RNeasy Mini kit (Qiagen) was used to isolate whole lung RNA 
from the lungs of CCSP-p52 and WT mice treated with dox for 1 week and with or without intratracheal LPS 
administration, which was performed as part of a separate study [described in ref.19]. To minimize the effects of 
mouse-to-mouse-variability, RNA was pooled from 3 mice for each sample, resulting in a total of 8 samples (2 
WT dox only, 2 WT with LPS, 2 CCSP-p52 dox only, 2 CCSP-p52 with LPS). RNA quality control, hybridization 
to the Affymetrix Mouse Gene 1.0 ST array, and array scanning were performed by the Vanderbilt Technologies 
for Advanced Genomics (VANTAGE) Core. Expression data have been deposited in Gene Expression Omnibus 
(Accession # GSE71648).
The Robust Multichip Average method46 implemented in R package “oligo” (v1.28.3)47 was employed to nor-
malize imported raw data. Probe sets interrogating control, unmapped, or intron sequences were ignored, leaving 
79% of probe sets for a differential expression analysis. Linear models and empirical Bayes methods implemented 
in R package “limma” (v3.20.8)48 were applied to estimate log fold changes and p-values for the p52-vs-WT effect. 
Since samples with and without LPS stimulation were processed and microarray profiled at the same time, we 
assumed the random data variations were similar across all samples and built a linear model across the eight 
samples accounting for both p52 and LPS experimental factors49. The coefficient (estimated log fold change) 
and p-value associated with the p52 factor were retrieved for the selection of differentially expressed genes. This 
method enabled us to isolate the specific effects of p52 and LPS, allowing us to focus only on genes changed by 
p52 over-expression and effectively giving us 4 samples per group (12 mice per group) for our gene expression 
comparisons. When selecting top-ranking p52-induced genes, only probe sets mapped to known genes with pos-
itive expression changes were considered.
Quantitative PCR. Quantitative real-time PCR was performed using Sybr Green PCR Master Mix 
(Applied Biosystems) and the following primer sets: Ccna2 F: AAGAGAATGTCAACCCCGAAAAA; R: 
ACCCGTCGAGTCTTGAGCTT (PrimerBank ID: 161353443c1), Top2a F: CAACTGGAACATATACTGCTCCG; 
R: GGGTCCCTTTGTTTGTTATCAGC (PrimerBank ID: 6755849a1), Ube2c F: CTCCGCCTTCCCTGAGTCA; 
R: GGTGCGTTGTAAGGGTAGCC (PrimerBank ID 21312888a1) and Gapdh (F: TGAGGACCAGGTTGTCTCCT 
R: CCCTGTTGCTGTAGCCGTAT)50–52. Expression values were normalized to Gapdh using the ΔCT method.
Statistics. Unpaired student t-tests were performed for comparisons between two groups. Values are pre-
sented as the mean ± SEM, and p ≤ 0.05 was considered statistically significant. Data were analyzed using 
GraphPad Prism 5.0 software (GraphPad Software, Inc.). Analysis of transcriptomic data is presented below.
Human lung cancer expression data analysis. Raw expression data for 513 lung adenocarcinoma 
patient samples, generated by the TCGA project, were accessed from the ICGC data portal (https://dcc.icgc.
org/; release 17). The raw RSEM values53 were multiplied by 106 to normalized values of Transcripts Per Million 
(TPM). Of these 513 samples, matched tumor samples and paracancerous normal samples were available for 54 
patients. A paired t-test was performed for each gene, and the resultant p-values were adjusted to false discovery 
rates using the Benjamini-Hochberg method54.
Of the 513 lung adenocarcinoma samples, 437 primary lung adenocarcinoma samples had accompanying 
survival outcome data. In each survival analysis, samples were divided into two groups of equal sizes (termed 
high-expression and low-expression groups) by considering the collective expression of p52-associated genes. 
R package “survival” (v2.37-7)55 was employed to conduct survival analyses. In survival analyses, survival time 
values were truncated to 5 years (1825 days) to reflect 5-year survival rates.
For the BATTLE study analysis, global gene expression profiles of normal lung and lung adenocarcinoma, as 
assessed by Human Gene 1.0 ST microarrays (Affymetrix, Sta. Clara, CA), were retrieved from Gene Expression 
Omnibus series GSE4345821,22. Raw data were analyzed using Affymetrix Gene Expression and Transcriptome 
Analysis Consoles.
Gene functional analysis. Functions enriched within p52-regulated genes were identified through a hyper-
geometric test with respect to GO terms56, using R package GOstats (v1.7.4)57. For each GO term, genes from the 
reference set of whole human genome protein-coding genes and the concerned set of p52-regulated genes were 
respectively identified, and a p-value indicative of enrichment significance was calculated and further adjusted to 
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the FDR using the Benjamini-Hochberg method54. Resultant GO terms were pruned to lowest common ancestors 
according to the Biological Process semantic topology.
From the Human Protein Reference Database (HPRD, v9)58, a connected protein interaction network was 
derived that comprised 9,218 nodes and 36,728 edges. p52-regulated genes were mapped to this HPRD network, 
and then the Steiner minimal tree algorithm59 was implemented to retrieve the most parsimonious subnetwork 
that joined together the terminal genes.
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